Randall Harris, MD, PhD

Professor
Epidemiology

Phone: 

614-292-4720

Email: 

harris.44@osu.edu
1841 Neil Ave.
306 Cunz Hall
Columbus, OH, 43210

Research Honor

Fellow, American Association for the Advancement of Science, 2008, for research showing that inhibition of the inducible cyclooxygenase-2 (COX-2) gene has significant anti-neoplastic effects against major forms of cancer.

Education: 

M.D., University of Nebraska 1983
Ph.D., Genetics, North Carolina State University 1974
M.S., Genetics, University of Nebraska 1971
Board Certifications: Clinical Pathology, Public Health

Selected Publications: 

Books

Harris RE.  Global Epidemiology of Cancer, Jones & Bartlett, 2015.

Harris RE. Epidemiology of Chronic Disease: Global Perspectives, Jones & Bartlett, 2012.

Harris RE.  Inflammation in the Pathogenesis of Chronic Diseases: the COX-2 Controversy, Springer, 2007.

Harris RE.  COX-2 Blockade in Cancer Prevention and Therapy.  Humana Press, 2003.

Articles

Harris RE, Casto BC, Harris ZM.  Cyclooxygenase-2 and the inflammogenesis of breast cancer.  World Journal of Clinical Oncology 5(4): 677-692, 2014.

Harris RE, Beebe J, Al Shafie GA.  Reduction in cancer risk by selective and non-selective cyclooxygenase 2 (COX-2) inhibitors.  J Exp Pharm, 4, 91-96,   2012.  

Harris RE. Cyclooxygenase-2 (COX-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammo-pharmacology. 17:1-13, 2009.

Harris RE, Beebe-Donk J, Alshafie GA. Similar reductions in the risk of human colon cancer by selective and non-selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 8 (237): Aug 14, 2008.

Harris RE, Beebe-Donk J, Alshafie GA. Reduced risk of human lung cancer by selective cyclooxygenase-2 (COX-2) blockade: results of a case control study. International Journal of Biological Sciences, 3(5): 328-334, 2007

Harris RE. COX-2 and the inflammogenesis of cancer. Subcellular Biochemistry, 42: 193-212, 2007.

Harris RE, Beebe-Donk JD, Alshafie GA. Cancer chemoprevention by selective cyclooxygenase-2 (COX-2) blockade: results of case control studies. Subcellular Biochemistry, 42: 83-126, 2007.

Harris RE; Beebe-Donk J; Alshafie GA. Reduction in the risk of human breast cancer by COX-2 inhibitors. Biomed Central (BMC). Cancer, 6:27, 2006.

Harris, RE, Beebe-Donk J.  Aspirin, ibuprofen, and other nonsteroidal anti-inflammatory drugs (NSAIDs) in cancer prevention: a critical review (Review).  Oncology Reports 13 (4), 559-583, 2005.

Harris RE.  Does the dose make the poison?  Science 308; 203, 2005.

Harris RE, Sparks A, McTiernan A, Anderson G, White E, Chlebowski RT,  Frid D, Jackson R.  Inverse association of breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women’s Health Initiative.  Cancer Research 63: 6096-6101, 2003.

Harris RE, Beebe-Donk J, Schuller HM.  Chemoprevention of lung cancer by non-steroidal anti-inflammatory drugs among cigarette smokers. Oncology Reports 9: 693-395, 2002.

Harris RE, Namboodiri KA, Beebe-Donk, J.  Inverse association of malignant melanoma and non-steroidal anti-inflammatory drugs (NSAIDs) in women.  Oncology Reports 8: 655-657, 2001.

Harris RE, Alshafie GA, Abou-Issa H, Seibert K.  Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor.  Cancer Research 60: 2101-2103, 2000.

Harris RE, Kasbari S, Farrar WB.  Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer.  Oncology Reports 6:71-73, 1999.

Joarder FS, Abou-Issa H, Robertson FM, Parrett ML, Alshafie G, and Harris RE.  Growth arrest of DMBA-induced mammary carcinogenesis with ibuprofen treatment in female sprague-dawley rats.  Oncology Reports 4:1271-1273, 1997.

Harris RE, Namboodiri KK, Farrar WB.  Nonsteroidal anti-inflammatory drugs and breast cancer.  Epidemiology 7:203-205, 1996.

Harris RE, Namboodiri KK, Farrar WB.  Epidemiologic study of non-steroidal anti-inflammatory drugs and breast cancer.  Oncology Reports 2: 591-592, 1995.

Harris RE, Zang EA, Anderson JI, Wynder EL.  Race and sex differences in lung cancer risk associated with cigarette smoking.  Intl J Epidemiology 22(4): 592-599, 1993.

Harris RE, Namboodiri KK, Wynder EL.  Breast cancer risk: Effects of estrogen replacement therapy and body mass.  J Natl Cancer Inst 84 (20): 1575-1582, 1992.

Harris RE, Hebert JR, Wynder EL.  Cancer risk in male veterans utilizing the veterans administration medical system.  Cancer 64: 1160-1168, 1989.

Harris RE, Wynder EL.  Breast cancer and alcohol consumption: a study in weak associations.  J Am Med Assoc 259(19): 2867-2871, 1988.

Harris RE, Lynch, HT, Guirgis HA.  Familial breast cancer: risk to the contralateral breast.  J Natl Cancer Inst 60: 955-960, 1978.

If this is your profile page, click here and login with your Ohio State Username (name.#) to edit.